Targeted therapy in combination with anticancer agents has shown to improve efficacy and side effects in this disease.4 In this study, we show through silencing and overexpressing RBBP6 in mt p53 and wt p53 breast cancer cell lines that restoring the functions of wt p53 sensitized cancer cells to anticancer agent through the activation of apoptosis machinery. Here, RBBP6 is linked to breast carcinoma.